Toni K. Choueiri

Research interests

Publications

• Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2312695

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00487-9

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00487-9

• Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2022 · https://doi.org/10.6004/jnccn.2022.0001

• Post-acute COVID-19 syndrome

  Nature Medicine · 2021 · 10.1038/s41591-021-01283-z

• Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2035716

• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2106391

• Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

  JAMA Network Open · 2021 · https://doi.org/10.1001/jamanetworkopen.2020.21869

• Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.02.024

• Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2026982

• Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.010

• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31187-9

• Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-1044-8

• NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

  Journal of the National Comprehensive Cancer Network · 2020 · https://doi.org/10.6004/jnccn.2020.0043

• Prostate cancer reactivates developmental epigenomic programs during metastatic progression

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-020-0664-8

• Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

  Cancer · 2020 · https://doi.org/10.1002/cncr.33033

• Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

  Nature Medicine · 2020 · 10.1038/s41591-020-0839-y

• Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30413-9

• A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis

  Nature Communications · 2019 · 10.1038/s41467-019-09277-9

• Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1816047

• NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

  Journal of the National Comprehensive Cancer Network · 2019 · https://doi.org/10.6004/jnccn.2019.0054

• Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)30723-8

• The Immune Landscape of Cancer

  Immunity · 2019 · https://doi.org/10.1016/j.immuni.2019.08.004

• Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

  Science · 2018 · 10.1126/science.aan5951

• The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

  Cell Reports · 2018 · https://doi.org/10.1016/j.celrep.2018.03.075

• Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

  Nature Medicine · 2018 · 10.1038/s41591-018-0053-3

• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1712126

• Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.5324

• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1613683

• Systemic Therapy for Metastatic Renal-Cell Carcinoma

  New England Journal of Medicine · 2017 · 10.1056/nejmra1601333

• Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30107-3

• Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma

  Cancer Cell · 2016 · https://doi.org/10.1016/j.ccell.2016.04.002

• Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

  Genome biology · 2016 · https://doi.org/10.1186/s13059-016-1092-z

• Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma

  Cancer Cell · 2016 · https://doi.org/10.1016/j.ccell.2016.04.002

• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1510665

• Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1510016

• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

  Cancer Discovery · 2015 · 10.1158/2159-8290.cd-15-0369

• The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71222-7

• Lack of reduction in racial disparities in cancer‐specific mortality over a 20‐year period

  Cancer · 2014 · https://doi.org/10.1002/cncr.28617

• The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

  Cancer Cell · 2014 · https://doi.org/10.1016/j.ccr.2014.07.014

• The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

  Cancer Cell · 2014 · https://doi.org/10.1016/j.ccr.2014.07.014

• Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1303989

• Marital Status and Survival in Patients With Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.49.6489

• External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(12)70559-4

• Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.1217

• Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.9129

• Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer

  JAMA · 2011 · https://doi.org/10.1001/jama.2011.1745

• Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.4809

• Kidney Cancer

  Journal of the National Comprehensive Cancer Network · 2009 · https://doi.org/10.6004/jnccn.2009.0043

• Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.13.3223

Current projects

No projects listed.